Clinical Trials Logo

Clinical Trial Summary

This study aims to investigate the clinical efficacy of baricitinib in patients with adult idiopathic inflammatory myositis (IIM). Half of the patients enrolled onto the study will receive 24 weeks of baricitinib from the baseline visit with a 12 week follow-up period. The other half of patients will receive 24 weeks of barcitinib treatment after an initial 12-week delay with a 4 week follow up period for safety.


Clinical Trial Description

Potential participants will attend a screening visit to confirm their eligibility to participate in the trial. Once eligibility is confirmed the participant will be randomised to receive 24 weeks of baracitinib from the baseline visit with 12 weeks of follow up or receive 24 weeks of baracitinib after a delayed-start of 12 weeks from the baseline visit. Participants will attend study visits every 4 weeks starting at the baseline visit at week 0. At each visit data will be collected about the following: 1. Muscle function 2. Signs of disease activity 3. Vital signs 4. Physical examination 5. A blood test to check blood count, liver and kidney function and markers of inflammation for safety purposes. 6. Participant reported assessment of how disease disease is progressing. In addition the following data will be collected at week 0, week 12, week 24 and week 36: 1. Signs of disease damage 2. Blood and urine sample collection for biomarker analysis 3. Additional muscle function and disease activity assessments 4. Participant reported assessment of how disease affects their day-to-day life. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04208464
Study type Interventional
Source University of Manchester
Contact
Status Completed
Phase Phase 2
Start date October 7, 2021
Completion date September 25, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT05833711 - Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy Phase 2
Recruiting NCT04561557 - Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System Early Phase 1
Completed NCT03267277 - Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Phase 2/Phase 3
Recruiting NCT06316076 - Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases Phase 1
Not yet recruiting NCT06350110 - Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) Phase 1/Phase 2
Recruiting NCT05879419 - Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Phase 4
Recruiting NCT04792931 - Adult Autoimmune Myopathies (MAIA) N/A
Not yet recruiting NCT06417398 - Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases Early Phase 1
Not yet recruiting NCT06285539 - Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases Phase 2
Recruiting NCT04664465 - PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS
Not yet recruiting NCT06152172 - CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101 Phase 1
Recruiting NCT05400889 - Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Idiopathic Inflammatory Myopathies Phase 2
Completed NCT03918356 - Application of Electrical Impedance Myography (EIM) as a Potential Biomarker of Idiopathic Inflammatory Myopathies N/A
Completed NCT00341679 - Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases
Recruiting NCT05952531 - Characterizing Myositis With 68Ga-FAPI PET/CT Early Phase 1
Recruiting NCT05200702 - Assessment of Safety and Acute Effects of a Knee-hip Powered Soft Exoskeleton in Patients With Neuromuscular Disorders N/A
Completed NCT03092167 - Physical Training in Patients With Idiopathic Inflammatory Myopathies N/A
Recruiting NCT03092180 - Optimizing Treatment on Idiopathic Inflammatory Myopathies
Recruiting NCT05199246 - Assessment of Safety and Acute Effects of a Lower-limb Powered Dermoskeleton in Patients With Neuromuscular Disorders N/A
Not yet recruiting NCT04034199 - Treating Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density With Denosumab or Zoledronic Acid Phase 3